Cardinal Health reported a strong Q4 adjusted EPS of $2.91, beating estimates by 20.25%, driven partly by a one-time tariff refund. Despite missing revenue expectations by nearly 3% with $63.7 billion, the company still achieved 6% year-over-year revenue growth. Core operations showed robust 25% growth in non-GAAP diluted EPS, indicating solid underlying performance. This mix of results highlights strong profitability amid slightly softer sales, important for investors assessing the healthcare supply chain leader's outlook.
Cardinal Health reported a 6% increase in Q4 revenue to $63.7 billion and a 70% rise in GAAP diluted EPS to $1.70, driven by strong pharmaceutical sales and tariff refunds. Fiscal year 2026 revenue grew 14% to $254.2 billion, with non-GAAP diluted EP...
Cardinal Health's Board of Directors approved a quarterly dividend of $0.5158 per share, payable on October 15, 2026, to shareholders recorded by October 1, 2026. The dividend will be paid out from the company's capital surplus. Cardinal Health is a ...
